Ozempic vs Compounded Semaglutide

Ozempic vs compounded semaglutide at a glance

Ozempic and compounded semaglutide are often compared because telehealth ads use the Ozempic name to sell compounded vials. They are different things. Ozempic is a specific FDA-approved diabetes drug with a label revised in May 2026. Compounded semaglutide is a pharmacy product that borrows the ingredient name and nothing else from that label.

The table lists the differences that change a purchase decision. The Ozempic column comes from the label and Novo Nordisk's pharmacy page; the compounded column comes from FDA's compounding pages.

Is compounded semaglutide the same as Ozempic?

No. FDA's position is that compounded drugs are not FDA-approved and receive no premarket review for safety, effectiveness, or quality. Ozempic is the reviewed product; a compounded semaglutide vial is a pharmacy preparation that shares an ingredient name and nothing else. It is not generic Ozempic, and no approved generic semaglutide exists.

There is a second difference specific to Ozempic. Its label covers adults with type 2 diabetes: improving glycemic control, reducing major adverse cardiovascular events in those with established cardiovascular disease, and reducing kidney outcomes in those with chronic kidney disease. Weight management is not an Ozempic indication. Novo Nordisk's separate product, Wegovy, carries the weight-management indications. A compounded semaglutide vial sold for weight loss is therefore being compared with a drug whose label is about a different condition.

FDA's September 2026 update counts 990 adverse-event reports for compounded semaglutide as of May 31, 2026, and flags salt forms such as semaglutide sodium and acetate as different ingredients from the approved drug. Those concerns apply to compounded products regardless of which brand name the marketing uses.

Who makes Ozempic and who compounds semaglutide

Novo Nordisk manufactures Ozempic. Compounded semaglutide comes from a 503A pharmacy, a state-licensed pharmacy compounding for individual prescriptions under state board oversight, or from a 503B outsourcing facility that registers with FDA and follows current good manufacturing practice. FDA explains that the two work under different quality standards, and that compounded drugs in general are not reviewed for safety, effectiveness, or quality before sale.

The 2025 shortage decisions changed the rules. FDA confirmed the semaglutide shortage resolved on February 21, 2025, and ended enforcement discretion on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. Under FDA's April 2026 clarification, a 503A pharmacy may not regularly compound essentially copies of a commercially available approved drug, and a 503B facility may not use bulk semaglutide because it is on neither the bulks list nor the shortage list. A program still selling compounded semaglutide should explain which facility fills it and on what basis.

How each one is dosed and stored

The Ozempic label starts at 0.25 mg once weekly for four weeks, then 0.5 mg weekly, with increases to 1 mg and 2 mg after at least four weeks on each dose if more glycemic control is needed. Ozempic ships as single-patient-use pens: a 2 mg/3 mL pen for 0.25 mg and 0.5 mg doses, a 4 mg/3 mL pen for 1 mg doses, and an 8 mg/3 mL pen for 2 mg doses, plus single-dose syringes. Before first use the pen stays refrigerated at 36°F to 46°F; after first use it lasts 56 days at room temperature or refrigerated and is then discarded, and the pen must never be shared.

Compounded semaglutide most often arrives as a multi-dose vial with a pharmacy-specific concentration, drawn up by the patient with a syringe on the prescriber's schedule. FDA reports dosing errors and doses beyond the approved label among the adverse-event reports and advises discarding a multi-dose vial 28 days after first use with a new sterile needle every time. Telehealth Ledger does not publish syringe-unit or concentration conversions.

The Ozempic label is a diabetes label, not a dosing guide for a compounded weight-loss product. Do not switch between the two without the prescriber and pharmacy confirming the product and concentration.

Where you buy Ozempic and where compounded semaglutide is sold

Ozempic is a prescription drug filled at retail pharmacies, through insurance, or through NovoCare Pharmacy, Novo Nordisk's self-pay home-delivery channel. NovoCare's page says all doses require a prescription, lists telehealth prescribers, free home delivery through its dispensing pharmacy CoAssist Pharmacy, and pharmacy pickup, and states plainly that if it is not made by Novo Nordisk it is not FDA-approved Ozempic. The same page now also lists an Ozempic pill alongside the pen.

Compounded semaglutide is sold through telehealth programs that bundle a clinician visit with a partner pharmacy's vial and ship it to the patient. FDA's consumer advice is to obtain the prescription from a licensed doctor, fill it at a state-licensed pharmacy, and treat sales without a prescription or clinician screening as a warning sign.

What Ozempic costs through Novo Nordisk and how compounded semaglutide is priced

NovoCare Pharmacy lists the Ozempic pen at $199 per month for the 0.25 mg and 0.5 mg doses for two monthly fills through December 31, 2026 for patients new to the program, then $349 per month for 0.25 mg, 0.5 mg, or 1 mg and $499 per month for 2 mg, with a month defined as one pen. The Ozempic pill is listed starting at $149 per month for a bottle of 30 tablets. Commercially insured patients may pay as little as $25 per month for up to three months with a $100 monthly savings cap.

Compounded semaglutide has no list price. Each telehealth program sets a monthly or prepaid figure that may or may not include the visit, the vial, supplies, and shipping. The catalog module below shows current telehealth prices for compounded semaglutide and Ozempic programs with their price basis and verification date. A telehealth Ozempic price above Novo Nordisk's own figure is paying for the program, not the drug.

What to ask a telehealth provider before choosing

These questions expose whether a program is selling Ozempic, compounded semaglutide, or an unclear mix, and what the monthly total will be.

• Is this FDA-approved Ozempic from Novo Nordisk, or a compounded semaglutide product? Which pharmacy fills it?
• If Ozempic, what is the diagnosis on the prescription, and does the program handle insurance or the NovoCare self-pay price?
• If compounded, is the ingredient base semaglutide or a salt form, what is the concentration, and what are the written measuring instructions?
• What does the monthly price include, and what is the continuing price after any introductory month?
• How is the product shipped and kept cold, and what happens if it arrives warm?
• What is the cancellation rule if the clinician does not prescribe or I stop?